|
"meng r"的相關文件
顯示項目 1-9 / 9 (共1頁)
1
每頁顯示[10|25|50]項目
| 臺大學術典藏 |
2022-09-15T01:08:45Z |
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: Results from a phase I/II open-label, multicenter study
|
Zucali P.A.; Chia-Chi Lin; Carthon B.C.; Bauer T.M.; Tucci M.; Italiano A.; Iacovelli R.; Su W.-C.; Massard C.; Saleh M.; Daniele G.; Greystoke A.; Gutierrez M.; Pant S.; Shen Y.-C.; Perrino M.; Meng R.; Abbadessa G.; Lee H.; Dong Y.; Chiron M.; Wang R.; Loumagne L.; L?pine L.; De Bono J. |
| 臺大學術典藏 |
2022-08-19T00:20:57Z |
Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study
|
Cheng A.-L.; Meng R.; Chao Y.; Hsieh T.-Y.; Huang W.-T.; Hwang W.-S.; Yu C.-W.; Hsieh R.-K.; Huo T.-I.; Yang T.-S.; CHIUN HSU |
| 臺大學術典藏 |
2022-02-21T02:51:54Z |
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: Results from a phase I/II open-label, multicenter study
|
Zucali P.A.; Lin C.-C.; Carthon B.C.; Bauer T.M.; Tucci M.; Italiano A.; Iacovelli R.; Su W.-C.; Massard C.; Saleh M.; Daniele G.; Greystoke A.; Gutierrez M.; Pant S.; YING-CHUN SHEN; Perrino M.; Meng R.; Abbadessa G.; Lee H.; Dong Y.; Chiron M.; Wang R.; Loumagne L.; L?pine L.; De Bono J. |
| 國立成功大學 |
2022 |
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: Results from a phase I/II open-label, multicenter study
|
Zucali, P.A.;Lin, C.-C.;Carthon, B.C.;Bauer, T.M.;Tucci, M.;Italiano, A.;Iacovelli, R.;Su, W.-C.;Massard, C.;Saleh, M.;Daniele, G.;Greystoke, A.;Gutierrez, M.;Pant, S.;Shen, Y.-C.;Perrino, M.;Meng, R.;Abbadessa, G.;Lee, H.;Dong, Y.;Chiron, M.;Wang, R.;Loumagne, Loumagne L.;L�pine, L�pine L.;De, Bono J. |
| 國立成功大學 |
2022 |
Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study
|
Simonelli, M.;Garralda, E.;Eskens, F.;Gil-Martin, Martin M.;Yen, C.-J.;Obermannova, R.;Chao, Y.;Lonardi, S.;Melichar, B.;Moreno, V.;Yu, M.-L.;Bongiovanni, A.;Calvo, E.;Rottey, S.;Machiels, J.-P.;Gonzalez-Martin, A.;Paz-Ares, L.;Chang, Chang C.-L.;Mason, W.;Lin, C.-C.;Reardon, D.A.;Vieito, M.;Santoro, A.;Meng, R.;Abbadessa, G.;Menas, F.;Lee, H.;Liu, Q.;Combeau, Combeau C.;Ternes, N.;Ziti-Ljajic, S.;Massard, C. |
| 臺大學術典藏 |
2021-09-01T01:54:01Z |
Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study
|
Hsu C.; Yang T.-S.; Huo T.-I.; Hsieh R.-K.; Yu C.-W.; Hwang W.-S.; Hsieh T.-Y.; Huang W.-T.; Chao Y.; Meng R.; ANN-LII CHENG |
| 臺大學術典藏 |
2020-07-09T02:57:03Z |
Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study
|
CHIH-WEI YU; Hwang W.-S.; Hsieh T.-Y.; Huang W.-T.; Chao Y.; Meng R.; Cheng A.-L.; Hsieh R.-K.; Huo T.-I.; Yang T.-S.; Hsu C. |
| 臺大學術典藏 |
2020-04-10T12:51:14Z |
Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study
|
Chiun Hsu;Yang T.-S.;Huo T.-I.;Hsieh R.-K.;Yu C.-W.;Hwang W.-S.;Hsieh T.-Y.;Huang W.-T.;Chao Y.;Meng R.;Cheng A.-L.; Chiun Hsu; Yang T.-S.; Huo T.-I.; Hsieh R.-K.; Yu C.-W.; Hwang W.-S.; Hsieh T.-Y.; Huang W.-T.; Chao Y.; Meng R.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:14Z |
Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study
|
Chiun Hsu;Yang T.-S.;Huo T.-I.;Hsieh R.-K.;Yu C.-W.;Hwang W.-S.;Hsieh T.-Y.;Huang W.-T.;Chao Y.;Meng R.;Cheng A.-L.; Chiun Hsu; Yang T.-S.; Huo T.-I.; Hsieh R.-K.; Yu C.-W.; Hwang W.-S.; Hsieh T.-Y.; Huang W.-T.; Chao Y.; Meng R.; Cheng A.-L. |
顯示項目 1-9 / 9 (共1頁)
1
每頁顯示[10|25|50]項目
|
